Engineered hematopoietic stem cells that unleash the potential of targeted therapies. Hide healthy cells, expose cancer cells.
Total raised: $352M
Investors 2
| Date | Name | Website |
| - | 5AM Ventur... | 5amventure... |
| - | RA Capital... | racap.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 10.02.2021 | IPO | $200M | - |
| 07.07.2020 | Series B | $110M | - |
| 14.02.2019 | Series A | $42M | - |
Mentions in press and media 16
| Date | Title | Description |
| 10.02.2021 | Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares | - |
| 17.07.2020 | Tony Kingsley takes over the reins at Scholar Rock; Idorsia taps pharma vet Patricia Torr for new US ops | Tony Kingsley → Scholar Rock — which partnered with Gilead back in 2018 for a discovery pact for fibrotic diseases — has passed the CEO and president baton down to Tony Kingsley, who is taking over from Nagesh Mahanthappa. K... |
| 08.07.2020 | Vor Biopharma Raises $110M Series B | CAMBRIDGE, MA, Vor Biopharma announced it has raised $110 million in a Series B financing. >> Click here for more funding data on Vor Biopharma >> To export Vor Biopharma funding data to PDF and Excel, click here Vor Biop... |
| 07.07.2020 | Vor Biopharma : Closes $110 Million Series B Financing | Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced it has raised $110 million in a Series B financing. Proceeds will advance the company’s lead candidate VO... |
| 07.07.2020 | Vor Biopharma Raises $110M In Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced it has raised $110 million in a Series B financing. Proceeds will adva... |
| 07.07.2020 | Vor Biopharma Closes $110 Million Series B Financing | - |
| 07.07.2020 | Vor Biopharma Closes $110 Million Series B Financing | - |
| 14.02.2019 | Vor Biopharma raises $42M in Series A round to advance AML cell therapy toward clinic | The company said it would use the funding to advance its hematopoietic stem cell-based therapy candidate for treating acute myeloid leukemia toward the clinic and further build its therapy pipeline. According to the company’s website, it is... |
| 14.02.2019 | Vor Biopharma Completes $42 Million Series A | BOSTON--(BUSINESS WIRE)--Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for the treatment of hematological malignancies, today announced a $42 million Series A financing round led by ... |
| 14.02.2019 | Term Sheet — Thursday, February 14 | THE KEY TO A BETTER PARTNERSHIP Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop Well, turns out there is at least one thing (that we thought of). We asked a number of venture inv... |
Show more